PROQR THERAPEUTICS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.94 USD | -1.02% |
|
-2.51% | -2.02% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 475.7 | 210.6 | 569.9 | 264.3 | 160.7 | 157.8 | - | - |
| Enterprise Value (EV) 1 | 367.6 | 210.6 | 410.2 | 169 | 160.7 | 157.8 | 157.8 | 157.8 |
| P/E ratio | -6.6 x | -3.69 x | -7.38 x | -3.75 x | -5.18 x | -4.36 x | -4.73 x | -3.87 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 226 x | 18.2 x | 210 x | 50.8 x | 15.5 x | 7.59 x | 8.21 x | 12.9 x |
| EV / Revenue | 226 x | 18.2 x | 210 x | 50.8 x | 15.5 x | 7.59 x | 8.21 x | 12.9 x |
| EV / EBITDA | - | - | -9.18 x | -3.92 x | -5.02 x | -2.76 x | -2.04 x | -1.78 x |
| EV / FCF | -9.72 x | -3.71 x | -19.3 x | -3.52 x | - | -6.92 x | -7.51 x | -2.55 x |
| FCF Yield | -10.3% | -27% | -5.18% | -28.4% | - | -14.4% | -13.3% | -39.2% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 48,004 | 50,146 | 71,155 | 71,435 | 81,157 | 81,355 | - | - |
| Reference price 2 | 9.910 | 4.200 | 8.010 | 3.700 | 1.980 | 1.940 | 1.940 | 1.940 |
| Announcement Date | 2/26/20 | 2/25/21 | 2/24/22 | 3/29/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.103 | 11.56 | 2.712 | 5.202 | 10.4 | 20.8 | 19.22 | 12.22 |
| EBITDA 1 | - | - | -62.06 | -67.38 | -32.04 | -57.09 | -77.54 | -88.86 |
| EBIT 1 | -62.49 | -51.79 | -64.7 | -70.11 | -34.78 | -39.97 | -46.47 | -61.54 |
| Operating Margin | -2,971.8% | -448.24% | -2,385.94% | -1,347.69% | -334.48% | -192.14% | -241.74% | -503.49% |
| Earnings before Tax (EBT) 1 | -61.59 | -56.83 | -69.64 | -70.19 | -30.37 | -32.31 | -33.98 | -50.23 |
| Net income 1 | -61.44 | -56.93 | -69.71 | -70.54 | -30.7 | -38.98 | -33.98 | -50.23 |
| Net margin | -2,921.88% | -492.65% | -2,570.75% | -1,355.91% | -295.21% | -187.41% | -176.78% | -410.96% |
| EPS 2 | -1.501 | -1.137 | -1.086 | -0.9858 | -0.3821 | -0.4450 | -0.4100 | -0.5007 |
| Free Cash Flow 1 | -48.96 | -56.78 | -29.52 | -74.98 | - | -22.81 | -21.01 | -61.91 |
| FCF margin | -2,328% | -491.38% | -1,088.51% | -1,441.4% | - | -109.63% | -109.31% | -506.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 2/25/21 | 2/24/22 | 3/29/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.341 | 0.5023 | 1.402 | 1.15 | 1.035 | 1.422 | 0.7578 | 1.359 | 1.472 | 6.786 | 2.857 | 2.857 | 8.337 | 5.618 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -6.049 | -13.24 | -13.9 | -14.61 | -15.35 |
| EBIT 1 | -16.86 | -19.6 | -17.8 | -16.1 | -19.78 | -13.39 | -10.21 | -9.636 | -7.939 | -6.844 | -9.908 | -10.43 | -10.91 | -8.707 |
| Operating Margin | -1,257.08% | -3,902.72% | -1,268.91% | -1,400.09% | -1,910.78% | -941.2% | -1,347.06% | -708.85% | -539.49% | -100.85% | -346.84% | -364.97% | -130.86% | -155% |
| Earnings before Tax (EBT) 1 | -17.41 | -20.61 | -15.17 | -14.99 | -24.43 | -12.34 | -9.627 | -8.77 | -5.866 | -5.981 | -8.333 | -8.8 | -9.216 | -6.026 |
| Net income 1 | -17.43 | -20.61 | -15.17 | -15.23 | -24.52 | -12.34 | -9.712 | -8.741 | -6.133 | -5.986 | -9.724 | -10.49 | -10.56 | -8.257 |
| Net margin | -1,299.39% | -4,103.85% | -1,081.8% | -1,324.47% | -2,368.45% | -867.25% | -1,281.64% | -643.04% | -416.79% | -88.22% | -340.42% | -367.23% | -126.69% | -146.98% |
| EPS 2 | -0.2548 | -0.2941 | -0.2101 | -0.2148 | -0.3417 | -0.1733 | -0.1196 | -0.1094 | -0.0752 | -0.0764 | -0.1104 | -0.1168 | -0.1190 | -0.0996 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/24/22 | 5/5/22 | 8/4/22 | 11/9/22 | 3/29/23 | 5/16/23 | 8/3/23 | 11/7/23 | 3/13/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 108 | - | 160 | 95.3 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -49 | -56.8 | -29.5 | -75 | - | -22.8 | -21 | -61.9 |
| ROE (net income / shareholders' equity) | - | - | -72.1% | -72.6% | - | -201% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.64 | 1.09 | 0.54 | 0.77 | - | 1.58 | 1.21 | 1.4 |
| Capex / Sales | 30.31% | 9.46% | 19.88% | 14.74% | - | 7.59% | 6.32% | 11.48% |
| Announcement Date | 2/26/20 | 2/25/21 | 2/24/22 | 3/29/23 | 3/13/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.94
USD
Average target price
4.1
USD
Spread / Average Target
+111.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.02% | 158M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PRQR Stock
- Financials ProQR Therapeutics N.V.
